Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • Cure & Immunotherapy
      • Brain & Mental Health
      • Therapeutics
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Early Career Investigator Program
    • Staff Spotlights
    • Funding Acknowledgements
    • Network Sites
      • Study Site Map
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
    • Spotlight Series
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Media Release Form
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Mark Mirochnick

Email

markm@bu.edu

Phone

617-414-3754

Institution

Department of Pediatrics, Boston University School of Medicine

Title

Address

Department of Pediatrics, Boston University School of Medicine
801 Albany Street, Room 2020

Boston, MA 02118
United States of America
Request an Update

Affiliated Studies

1077FF: PROMISE 1077FF

DAIDS Number

10778

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

38637

Research Area

Therapeutics

Study Status

Closed to Accrual

P1026S: PK in Pregnancy

DAIDS Number

Therapeutics

Research Area

Treatment

Study Status

Closed to Follow Up

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

DAIDS Number

11882

Research Area

Therapeutics

Study Status

Closed to Follow Up

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States

DAIDS Number

38746

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Sitemap Privacy Notice

© 2020 IMPAACT Network